[go: up one dir, main page]

CR6577A - Inhibidores triciclicos de poli(adp-ribosa) polimerasas - Google Patents

Inhibidores triciclicos de poli(adp-ribosa) polimerasas

Info

Publication number
CR6577A
CR6577A CR6577A CR6577A CR6577A CR 6577 A CR6577 A CR 6577A CR 6577 A CR6577 A CR 6577A CR 6577 A CR6577 A CR 6577A CR 6577 A CR6577 A CR 6577A
Authority
CR
Costa Rica
Prior art keywords
adp
inhibitors
ribosa
tricycle
polymerases
Prior art date
Application number
CR6577A
Other languages
English (en)
Inventor
Evan Webber Stephen
James Skalitzky Donald
Girish Tikhe Jayashree
Arnold Kumpf Robert
Timothy Marakovits Joseph
Walter Eastman Brian
Original Assignee
Agouron Pharmaceuticals Inc Y Cancer Res Compaing Techn
Cancer Res Campaing Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals Inc Y Cancer Res Compaing Techn, Cancer Res Campaing Technology Ltd filed Critical Agouron Pharmaceuticals Inc Y Cancer Res Compaing Techn
Publication of CR6577A publication Critical patent/CR6577A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPONENTES DE LA FORMULA (I) ON INHIBIDORES DE TRANSFERENCIA DE LOS POLI(ADP-RIBOSIL). DICHOS COMPUESTOS SON UTILES COMO TERAPEUTIOS EN EL TRATAMIENTO DE CANCERES Y EN MEJORAR LOS EFECTOS DE INFARTOS, TRAUMAS EN LA CABEZA Y ENFERMEDADES NEURODEGENERATIVAS.
CR6577A 1999-08-31 2002-02-01 Inhibidores triciclicos de poli(adp-ribosa) polimerasas CR6577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
CR6577A true CR6577A (es) 2003-12-05

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6577A CR6577A (es) 1999-08-31 2002-02-01 Inhibidores triciclicos de poli(adp-ribosa) polimerasas

Country Status (48)

Country Link
US (1) US6548494B1 (es)
EP (1) EP1208104B1 (es)
JP (1) JP4272375B2 (es)
KR (1) KR20020038742A (es)
CN (1) CN1384835A (es)
AP (1) AP1553A (es)
AR (1) AR035162A1 (es)
AT (1) ATE287406T1 (es)
AU (1) AU781826B2 (es)
BG (1) BG106562A (es)
BR (1) BR0015051A (es)
CA (1) CA2382404C (es)
CO (1) CO5200769A1 (es)
CR (1) CR6577A (es)
CZ (1) CZ2002613A3 (es)
DE (1) DE60017575T2 (es)
DK (1) DK1208104T3 (es)
DO (1) DOP2000000069A (es)
DZ (1) DZ3216A1 (es)
EA (1) EA200200306A1 (es)
EC (1) ECSP003637A (es)
EE (1) EE200200100A (es)
ES (1) ES2234657T3 (es)
GE (1) GEP20043268B (es)
GT (1) GT200000145A (es)
HK (1) HK1045509B (es)
HR (1) HRP20020271A2 (es)
HU (1) HUP0202703A3 (es)
IL (1) IL147863A0 (es)
IS (1) IS6289A (es)
MA (1) MA25876A1 (es)
MX (1) MXPA02002138A (es)
MY (1) MY135910A (es)
NO (1) NO322475B1 (es)
NZ (1) NZ516793A (es)
OA (1) OA12016A (es)
PA (1) PA8501801A1 (es)
PE (1) PE20010538A1 (es)
PL (1) PL354242A1 (es)
PT (1) PT1208104E (es)
SI (1) SI1208104T1 (es)
SK (1) SK2592002A3 (es)
SV (1) SV2003000162A (es)
UA (1) UA73144C2 (es)
UY (1) UY26323A1 (es)
WO (1) WO2001016136A2 (es)
YU (1) YU15102A (es)
ZA (1) ZA200200830B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
PL347885A1 (en) * 1999-09-28 2002-04-22 Basf Ag Azepinoindole derivatives, the production and use thereof
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
DE602004015724D1 (de) 2003-01-09 2008-09-25 Pfizer Diazepinoindolderivate als kinaseinhibitoren
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PT1660095E (pt) * 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
DK1684736T3 (da) * 2003-12-01 2011-11-21 Kudos Pharm Ltd Inhibitorer af DNA-skadereparation til behandling af cancer
MX2007003311A (es) * 2004-09-22 2007-05-16 Pfizer Procedimiento para preparar inhibidores de poli (adp-ribosa) polimerasas.
JP5201995B2 (ja) * 2005-01-19 2013-06-05 エーザイ インク． ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法
WO2006138195A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
JPWO2006137510A1 (ja) 2005-06-24 2009-01-22 小野薬品工業株式会社 脳血管障害時における出血低減剤
CN101242822B (zh) * 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
BRPI0614168A2 (pt) * 2005-08-05 2017-07-25 Astrazeneca Ab Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
CN101534836B (zh) * 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
US8143447B2 (en) * 2006-09-05 2012-03-27 Bipar Sciences, Inc. Treatment of cancer
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
NZ581364A (en) 2007-06-05 2011-10-28 Nsab Af Neurosearch Sweden Ab Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US7981890B2 (en) 2007-09-14 2011-07-19 Astrazeneca Ab Phthalazinone derivatives
EP2217244A4 (en) * 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
RU2480211C2 (ru) * 2007-11-12 2013-04-27 Байпар Сайенсиз, Инк. Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
WO2009073869A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CN101999002A (zh) * 2008-02-04 2011-03-30 彼帕科学公司 诊断和治疗parp-介导的疾病的方法
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
UA106878C2 (uk) 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
JP2015533783A (ja) * 2012-09-05 2015-11-26 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 非生物的な植物ストレスに対する活性物質としてのベンゾジアゼピノン類及びベンゾアゼピノン類又はそれらの塩の使用
WO2015103526A1 (en) * 2014-01-05 2015-07-09 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
DK3325623T6 (da) 2015-07-23 2021-03-15 Inst Curie Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3615026B1 (en) 2017-04-28 2021-03-03 Akribes Biomedical GmbH A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
CN111819282A (zh) 2018-03-13 2020-10-23 欧恩科斯欧公司 对抗癌症治疗中获得性耐药性的Dbait分子
EP3813827A4 (en) 2018-06-28 2022-04-13 Jiangsu Hengrui Medicine Co., Ltd. FUSIONED TRICYCLIC HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
WO2020124059A1 (en) * 2018-12-14 2020-06-18 Eternity Bioscience Inc. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
WO2021007435A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL297537A (en) 2020-04-28 2022-12-01 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
JP2024503380A (ja) 2021-01-08 2024-01-25 サイブレクサ ２，インコーポレイテッド コンジュゲート連結部分を調製するための方法
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (es) 1964-03-24
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
EP0670831A1 (en) 1993-09-28 1995-09-13 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
CA2225465A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
CA2289119C (en) 1997-05-13 2011-03-15 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using padprt inhibitors
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999059973A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
EP1077946A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity

Also Published As

Publication number Publication date
DE60017575T2 (de) 2005-06-09
EA200200306A1 (ru) 2002-08-29
KR20020038742A (ko) 2002-05-23
WO2001016136A3 (en) 2001-06-21
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
EP1208104A2 (en) 2002-05-29
GT200000145A (es) 2002-02-21
UA73144C2 (en) 2005-06-15
DK1208104T3 (da) 2005-05-02
PA8501801A1 (es) 2002-08-26
AU7338900A (en) 2001-03-26
GEP20043268B (en) 2004-06-25
BR0015051A (pt) 2002-06-25
AR035162A1 (es) 2004-05-05
IS6289A (is) 2002-02-27
CN1384835A (zh) 2002-12-11
PE20010538A1 (es) 2001-05-22
SI1208104T1 (en) 2005-06-30
NO20020421D0 (no) 2002-01-28
PL354242A1 (en) 2003-12-29
CA2382404C (en) 2009-03-24
NZ516793A (en) 2004-03-26
MA25876A1 (fr) 2003-10-01
DE60017575D1 (de) 2005-02-24
HK1045509B (zh) 2005-04-29
JP2003513015A (ja) 2003-04-08
IL147863A0 (en) 2002-08-14
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
NO20020421L (no) 2002-04-25
CA2382404A1 (en) 2001-03-08
MXPA02002138A (es) 2003-08-20
UY26323A1 (es) 2001-04-30
HUP0202703A2 (hu) 2002-12-28
PT1208104E (pt) 2005-04-29
ATE287406T1 (de) 2005-02-15
CO5200769A1 (es) 2002-09-27
EP1208104B1 (en) 2005-01-19
BG106562A (bg) 2003-03-31
NO322475B1 (no) 2006-10-09
JP4272375B2 (ja) 2009-06-03
DOP2000000069A (es) 2002-08-30
HK1045509A1 (en) 2002-11-29
AU781826B2 (en) 2005-06-16
DZ3216A1 (fr) 2001-03-08
MY135910A (en) 2008-07-31
ZA200200830B (en) 2003-03-26
AP1553A (en) 2006-01-18
HUP0202703A3 (en) 2004-12-28
CZ2002613A3 (cs) 2002-08-14
YU15102A (sh) 2004-12-31
WO2001016136B1 (en) 2001-11-15
HRP20020271A2 (en) 2005-12-31
EE200200100A (et) 2003-06-16
SK2592002A3 (en) 2002-10-08
ECSP003637A (es) 2002-03-25
ES2234657T3 (es) 2005-07-01

Similar Documents

Publication Publication Date Title
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
CR10370A (es) Derivados sustituidos de pirrolo-pirazol inhibidores de quinasa (divisional exp. 7880)
PA8496301A1 (es) Inhibidores de metaloproteasas.
DK1558616T4 (da) Meso-substituerede porphyriner
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
DK1147089T3 (da) Phenylphenanthridiner med PDE-IV-inhiberende virkning
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
BR0206161A (pt) 2-fenil benzimidazóis e imidazo-[4,5]-piridinas como inibidores de cds1/chk2 e adjuvantes para quimioterapia ou terapia por radiação no tratamento de câncer
AR027355A1 (es) Acidos tiazolidincarboxilicos
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
CO5700775A2 (es) Nuevos derivados triciclicos como antagonistas de ltd4
UY28049A1 (es) Derivados de (6,7-dihidro-5h-imidazo(1,2-a) imidazol-3-sulfonilamino)-propionamida
ATE368649T1 (de) Cyanoguanidin prodrugs
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
UY29532A1 (es) Derivados del ácido 6,7-dihidro-5h-imidazo(1,2-a)imidazol-3-sulfónico
DK1841765T3 (da) Imidazo[4,5-C]pyridinforbindelse og fremgangsmåde til antiviral behandling
NO20053903L (no) Nukleotidlipidesterderivater.
ATE335742T1 (de) Carbolinderivate als pdev inhibitoren
UY26498A1 (es) Pirroles sustituidos
BRPI0415038A (pt) derivados de imidazo (4,5-b) piridina como inibidores sem ser da sintase que podem ser induzidos
ATE531698T1 (de) 4-aminocarbonylamino-substitutierte imidazolverbindungen mit antiviraler wirkung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)